<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">JCI Insight</journal-id>
<journal-id journal-id-type="iso-abbrev">JCI Insight</journal-id>
<journal-id journal-id-type="publisher-id">JCI Insight</journal-id>
<journal-title-group>
<journal-title>JCI Insight</journal-title>
</journal-title-group>
<issn pub-type="epub">2379-3708</issn>
<publisher>
<publisher-name>American Society for Clinical Investigation</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30762586</article-id>
<article-id pub-id-type="pmc">6483011</article-id>
<article-id pub-id-type="publisher-id">124629</article-id>
<article-id pub-id-type="doi">10.1172/jci.insight.124629</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Targeting MRTF/SRF in CAP2-dependent dilated cardiomyopathy delays disease onset</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Xiong</surname>
<given-names>Yao</given-names>
</name>
<email>xiongyao@pennmedicine.upenn.edu</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bedi</surname>
<given-names>Kenneth</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Berritt</surname>
<given-names>Simon</given-names>
</name>
<email>simon.berritt@pfizer.com</email>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Attipoe</surname>
<given-names>Bennette K.</given-names>
</name>
<email>Bennette.Attipoe@pennmedicine.upenn.edu</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6980-0079</contrib-id>
<name>
<surname>Brooks</surname>
<given-names>Thomas G.</given-names>
</name>
<email>thobr@sas.upenn.edu</email>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Kevin</given-names>
</name>
<email>kaiwenw@seas.upenn.edu</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-8093-4465</contrib-id>
<name>
<surname>Margulies</surname>
<given-names>Kenneth B.</given-names>
</name>
<email>Kenneth.Margulies@uphs.upenn.edu</email>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-7161-7284</contrib-id>
<name>
<surname>Field</surname>
<given-names>Jeffrey</given-names>
</name>
<email>jfield@upenn.edu</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Systems Pharmacology and Translational Therapeutics,</aff>
<aff id="A2"><label>2</label>Cardiovascular Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.</aff>
<aff id="A3"><label>3</label>Department of Chemistry, Merck High throughput Experimentation Laboratory, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</aff>
<aff id="A4"><label>4</label>Institute of Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</aff>
<author-notes>
<corresp>Address correspondence to: Jeffrey Field, Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, 1313 BRB 2-3 Building, 421 Curie Blvd.,Philadelphia, Pennsylvania 19104, USA. Phone: 215.898.1912; Email: <email>jfield@upenn.edu</email>.</corresp>
<fn fn-type="COI-statement">
<p><bold>Conflict of interest:</bold> The authors have declared that no conflict of interest exists.</p>
</fn>
</author-notes>
<pub-date date-type="pub" iso-8601-date="2019-03-21T09:00:00-0400" publication-format="electronic">
<day>21</day>
<month>3</month>
<year>2019</year>
</pub-date>
<pub-date date-type="collection" iso-8601-date="2019-03-21T09:00:00-0400" publication-format="electronic">
<day>21</day>
<month>3</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>21</day>
<month>3</month>
<year>2019</year>
</pub-date>
<!-- PMC Release delay is 0 months and
						0 days and was based on the <pub-date
						pub-type="epub"/>. -->
<volume>4</volume>
<issue>6</issue>
<elocation-id>e124629</elocation-id>
<history>
<date date-type="received">
<day>31</day>
<month>8</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>12</day>
<month>2</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2019, American Society for Clinical Investigation</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder>American Society for Clinical Investigation</copyright-holder>
</permissions>
<self-uri xlink:href="https://insight.jci.org/articles/view/124629">This article is available online at https://insight.jci.org/articles/view/124629</self-uri>
<abstract>
<p>About one-third of dilated cardiomyopathy (DCM) cases are caused by mutations in sarcomere or cytoskeletal proteins. However, treating the cytoskeleton directly is not possible because drugs that bind to actin are not well tolerated. Mutations in the actin binding protein CAP2 can cause DCM and KO mice, either whole body (CAP2-KO) or cardiomyocyte-specific KOs (CAP2-CKO) develop DCM with cardiac conduction disease. RNA sequencing analysis of CAP2-KO hearts and isolated cardiomyocytes revealed overactivation of fetal genes, including serum response factor–regulated (SRF-regulated) genes such as Myl9 and Acta2 prior to the emergence of cardiac disease. To test if we could treat CAP2-KO mice, we synthesized and tested the SRF inhibitor CCG-1423-8u. CCG-1423-8u reduced expression of the SRF targets Myl9 and Acta2, as well as the biomarker of heart failure, Nppa. The median survival of CAP2-CKO mice was 98 days, while CCG-1423-8u–treated CKO mice survived for 116 days and also maintained normal cardiac function longer. These results suggest that some forms of sudden cardiac death and cardiac conduction disease are under cytoskeletal stress and that inhibiting signaling through SRF may benefit DCM by reducing cytoskeletal stress.</p>
</abstract>
<abstract abstract-type="toc">
<p>In mice, loss of the actin binding protein CAP2 causes dilated cardiomyopathy and serum response factor (SRF) activation, which can be targeted using an SRF inhibitor.</p>
</abstract>
<kwd-group kwd-group-type="specialties">
<kwd>Cardiology</kwd>
<kwd>Therapeutics</kwd>
</kwd-group>
<kwd-group kwd-group-type="keywords">
<kwd>Transcription</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution>National Heart, Lung, and Blood Institute</institution>
<institution-id>https://doi.org/10.13039/100000050</institution-id>
</institution-wrap>
</funding-source>
<award-id>R01HL134923-01</award-id>
</award-group>
</funding-group>
</article-meta>
</front>
</article>
</pmc-articleset>